Homology Medicines (FIXX) said Monday that the US Food and Drug Administration has lifted a clinical hold on a trial of the company's HMI-102...
Homology Medicines (FIXX) has an average rating of outperform and price targets ranging from $4 to $29, according to analysts polled by Capital IQ. (MT...
(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
Homology Medicines (FIXX) has an average rating of outperform and price targets ranging from $4 to $29, according to analysts polled by Capital IQ. (MT...
| Address | One Patriots Park Bedford, Massachusetts 01730 |
| Phone | +1.781.301.7277 |
| Number of Employees | 124 |
| Recent SEC Filing | 06/17/2022 4 |
| Chief Executive Officer & Director | Arthur O. Tzianabos |
| President & Chief Scientific Officer | Albert Seymour |
| Senior VP, Head-Clinical Development & Operations | Julie Jordan |
| Treasurer, Chief Financial & Business Officer | W. Bradford Smith |
| Price Open | $1.91 |
| Previous Close | $1.97 |
| 52 Week Range | $1.30 - 8.90 |
| Market Capitalization | $113.0 M |
| Shares Outstanding | 57.4 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 08/11/2022 |
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
| Price / Earnings | N/A |
| Earnings per Share | -$0.07 |
| Beta vs. S&P 500 | N/A |
| Revenue | $3.7 M |
| Net Profit Margin | -47.29% |
| Return on Equity | -1.20% |
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |
